Chest Meeting
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


COPYRIGHT © 2007 by the American College of Chest Physicians.
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jasuja, S.
Right arrow Articles by Marantz, S. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Jasuja, S.
Right arrow Articles by Marantz, S. G.

Respiratory Infections: Mycobacterial Disease Evaluation


Monday, October 22, 2007

10:30 AM - 12:00 PM

LATENT TUBERCULOSIS INFECTION SCREENING OF FOREIGN BORN PATIENTS USING QUANTIFERON-GOLD (QFT-G) IN SUBURBAN COOK COUNTY TB CLINICS IN ILLINOIS

Supriya Jasuja, MD, MPH, Anna Lee, MD, Raymond Macdonald, MD and Susan G. Marantz, MD, MPH*

Suburban Cook County Tuberculosis Sanitarium District, Forest Park, IL

PURPOSE: The value of QFT-G as a promising alternative to the tuberculin skin test (TST) in the diagnosis of latent tuberculosis infection (LTBI) can be illuminated by reports on actual test completion and the subsequent evaluation and treatment for patients with positive test results.

METHODS: In May 2006, pilot testing of QFT-G in foreign born patients began in 3 TB clinics in SCC where over 2400 LTBI cases are treated annually. Criteria for testing were based on FDA recommendations. Those with positive QFT-G were asked to return for evaluation. Retrospective chart review was performed on patients with a positive QFT-G test.

RESULTS: From May 2006 to March 2007, a total of 1914 QFT-G were done; 402/1914 (21%) results were positive, 50/1914 (3%) indeterminate, 1462/1914 (76%) negative. To date, 246 LTBI patients (58% female) with positive QFT-G were reviewed for age, sex, country of birth, risk for TB, reason for TB screening and LTBI treatment. 8/246 (3%) patients did not return for evaluation. Most common reasons for TB screening were work (52%), immigration (14%) and school (12%). 94% patients were born in a country where BCG is routinely offered with highest frequency born in Mexico (37%), India (13%) and Philippines (11%). Sixteen people (7%) were contacts considered to be high risk patients. 224 (91%) patients were prescribed chemoprophylaxis with either isoniazid (INH) 175/224(78%) or rifampin (RIF) 35/224 (16%) or combination of the two 13/224 (6%). To date, treatment has been completed in 22 (9%) and has been discontinued in 81(33%) due to adverse effects or noncompliance. 38% treated with RIF completed treatment compared to 14% treated with INH.

CONCLUSION: In a large foreign born BCG vaccinated cohort, QFT-G was well accepted. Increased specificity of the test may have led to a 28% decrease in the number of LTBI cases in our clinic from 2005 to 2006. Further testing and analysis is required to determine the overall clinical utility of QFT-G.

CLINICAL IMPLICATIONS: Quantifuron-G may be useful in eliminating unnecessary LTBI treatment.

DISCLOSURE: Susan Marantz, No Financial Disclosure Information; No Product/Research Disclosure Information




This article has been cited by other articles:


Home page
Proc Am Thorac SocHome page
D. J. Eckert and A. Malhotra
Pathophysiology of Adult Obstructive Sleep Apnea
Proceedings of the ATS, February 15, 2008; 5(2): 144 - 153.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Chest Physicians.